Atezolizumab for Lung Cancer Treatment
Lung cancer is a leading cause of cancer death at a global level. Atezolizumab, trade name Tecentriq, is indicated for patients with metastatic non-small cell lung cancer (NSCLC). It offers a new second-line therapeutic strategy for patients suffering from advanced NSCLC. It is an FDA approved drug for treatment of lung cancer that has spread or grown and chemotherapy containing platinum did not work. It is the first and only anti-PD-L1 cancer immunotherapy which is approved by FDA.
The recommended dosage is 1200mg and is administrated via intravenous infusion over 60 minutes every three weeks until disease progression. The dosage depends on the patient’s condition, the severity of cancer, and more. It works to remove the inhibitor effects and thereby offers an anti-tumor response. It is one of the several ways to block inhibitory signals related to T-cell activation. The studies have suggested the effect of this drug on the treatment for lung cancer. It is always recommended to consult your doctor before starting intake of any new drug.
Common Side Effects
Tencentriq can cause your immune system to attach normal organs in many areas of your body. The patients should be aware that it can cause infection and severe immune-mediated side effects. The most common side effects include fatigue, nausea, fever, constipation etc. It may cause serious side effects including liver problems, diarrhea, or severe stomach pain. If you face any side effects, you should immediately consult your health practitioner.
Precautions to be Taken
Before you receive Atezolizumab, you should tell your health care provider about all your medical conditions such as if you have immune system problems, or are pregnant/planning to become pregnant. Also, you should not breastfeed during the treatment and for at least five months after last dose of the drug.
Share your thoughts on the story in the comments.
All information offered in this blog is for educational purposes only and is not a substitute for medical advice.